Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|March 15, 2021

Treating Symptoms of Dementia-Related Psychosis

Author(s)Gary W. Small, MD

About 2.4 million people in the US experience dementia related psychosis, yet only half ever receive a diagnosis.

Gary Small, MD, talks about dementia-related psychosis and the one of the tools he's utilizing to help: Acadia Pharmaceutical's morethanmemoryloss.com.

Dr Small is Chair of Psychiatry and Physician in Chief for Behavioral Health at Hackensack Meridian Health.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Morning Rounds: News From August 10-16

ByJessica Walters

August 17th 2026

gguy/Adobe Stock

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

ByJessica Walters

August 14th 2026

schizophrenia

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

ByNicole C. Sears, NP,Michael M. Halassa, MD, PhD

August 13th 2026

bipolar

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

ByPragyan Sharma, MD, MSc,Samara White, PharmD,Ranel Troy Santos, PharmD, BCPP

August 5th 2026

Alzheimer

The State of Alzheimer Disease Care: An Update From Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

ByLeah Kuntz,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

August 3rd 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

A Practical Role for Long-Acting Buprenorphine in Opioid Use Disorder Care

Psyched Perspectives: ADHD in Underrecognized Populations, With Paige Walton, MD

Kratom Component in Clinical Trial for Opioid Use Disorder

Objective Measurement for Psychiatry: Universal Brain's ERP System